IMPAX has developed a portfolio of generic pharmaceuticals through the filing of Abbreviated New Drug Applications (ANDAs). Our generic product development strategy is based on a combination of speed to filing and a legal strategy primarily predicated upon non-infringement of established brand name pharmaceuticals.

Our generic products are marketed through strategic alliances as well as through our own generics division, Global Pharmaceuticals. Global sells the products to an established customer base, which includes large pharmaceutical wholesalers, chain drug stores, mass merchandisers and mail order pharmacies.

Our generic product development strategy is based on two opportunities we've identified in the generic pharmaceutical marketplace:

Controlled-release Generic Products
Through our controlled-release drug delivery technologies and formulation skills we develop bioequivalent versions of selected brand name pharmaceuticals. Controlled-release pharmaceuticals generally have technically challenging drug delivery requirements. We employ our proprietary processes and formulation expertise to develop products that reproduce the brand name product’s physiological characteristics, but do not infringe upon the brand product’s patents..

Specialty Generic Products
Products that present one or more competitive barriers to entry, such as difficulty sourcing raw material, complex formulation or development characteristics, or special handling requirements.